NCT05142709Completed
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1197 (actual)
- First submitted
- 31 Oct 2021
- Start date
- 31 Oct 2021
- Primary completion date
- 30 Sept 2023
- Lead sponsor
- Fudan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05142709
What you commit to
- Study type: Observational
- Participants enrolled: 1197
- From 31 Oct 2021 to the primary completion date, 30 Sept 2023
- 23 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are prior exposure to immune-mediated therapy.
Who the study is looking for
- Age \> 18, had an Eastern Cooperative Oncology Group performance status score of 0-3; Patients had unresectable or recurrent disease that precluded esophagectomy or definitive chemoradiation, or distant metastatic disease; Patients had received no previous systemic therapy (patients who had progressed ≥6 months after \[neo\]adjuvant therapy or definitive chemoradiation were eligible); Patients accepted at least one cycle of anti-PD-1 immunotherapy as 1st line treatment, combined chemotherapy was allowed.
- Patients who provided informed consent by appropriate methods. In dead case, optout will be applicable.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (23)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anyang Cancer Hospital Coordinator of this site? Confirm its status | Anyang | China | Unknown status |
| The 2nd affiliated hospital of Bengbu medical University Coordinator of this site? Confirm its status | Bengbu | China | Unknown status |
| Zhongnan University Xiangya Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| Sichuan Cancer Hospital Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Fujian Cancer Hospital & Fujian Medical University Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| The 2nd people's hospital of Anhui province Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Huai'an first hospital Coordinator of this site? Confirm its status | Huai'an | China | Unknown status |
| The 2nd affiliated hospital of Nanchang University Coordinator of this site? Confirm its status | Nanchang | China | Unknown status |
| Jiangxi Cancer Hospital Coordinator of this site? Confirm its status | Nanchang | China | Unknown status |
| The 1st affiliated hospital of Nanchang University Coordinator of this site? Confirm its status | Nanchang | China | Unknown status |
| JiangSu Cancer Hosipital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| Nantong Cancer Hospital Coordinator of this site? Confirm its status | Nantong | China | Unknown status |
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen Center Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
| The 4th affiliated hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
| The 2nd affiliated hospital of Wenzhou medical university Coordinator of this site? Confirm its status | Wenzhou | China | Unknown status |
| Wuhan University Zhongnan Hospital Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
| The 1st affiliated hospital of Xiamen University Coordinator of this site? Confirm its status | Xiamen | China | Unknown status |
| The First Affiliated Hospital of Air Force Medical University Coordinator of this site? Confirm its status | Xi’an | China | Unknown status |
| Yancheng the 3rd hospital Coordinator of this site? Confirm its status | Yancheng | China | Unknown status |
| The Northern Jiangsu People's Hospital Coordinator of this site? Confirm its status | Yangzhou | China | Unknown status |
| Henan Cancer Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
Related publications
- The role of thoracic radiotherapy in the setting of immunotherapy in polymetastatic esophageal squamous cell carcinoma: a multi-center cohort study.Ther Adv Med Oncol · 2026 · PMID 41696558
This page is information, not medical advice. Discuss any trial with your doctor.